Article Figures & Data
Figures
- FIGURE 1.
Baseline 18F-FDG PET findings in MCI patient who showed clinical progression to DAT within 16 mo. Surface projections of statistical abnormalities (z scores) as compared with healthy control population are displayed. Predefined anatomic surface ROIs are depicted in white color. Significant hypometabolism in bilateral temporoparietal and frontal cortex and in the posterior cingulate cortex is apparent. (A) Right lateral. (B) Left lateral. (C) Left medial. (D) Right medial.
- FIGURE 2.
Correct prediction concerning emergence of DAT in MCI patients. True- and false-positive and -negative findings of PET, APOE genotype, and combined PET/APOE classifications. PET: MCI patients with Alzheimer-suggestive PET scan at baseline were classified as test positive; APOE: MCI patients with APOE ε4–positive genotype were classified as test positive; PET and APOE: MCI patients with Alzheimer-suggestive PET scan and APOE ε4–positive genotype at baseline were classified as test positive; PET or APOE: MCI patients with Alzheimer-suggestive PET scan or APOE ε4–positive genotype were classified as test positive.
- FIGURE 3.
ROC analysis for PET, APOE genotyping, and combined approaches. PET: MCI patients with Alzheimer-suggestive PET scan at baseline were classified as test positive; APOE: MCI patients with APOE ε4–positive genotype were classified as test positive; PET and APOE: MCI patients with Alzheimer-suggestive PET scan and APOE ε4–positive genotype at baseline were classified as test positive; PET or APOE: MCI patients with Alzheimer-suggestive PET scan or APOE ε4–positive genotype were classified as test positive.
Tables
Follow-up diagnosis DAT No DAT P value n 12 18 — Sex (F/M) 6/6 10/8 0.94 Age at baseline*(y) 74.7 ± 4.7 67.6 ± 8.2 0.01 MMSE score at baseline* 25.9 ± 2.1 27.6 ± 1.5 0.02 MMSE score at follow-up* 22.6 ± 2.5† 27.2 ± 2.2 <0.001 APOE genotype (ε4–positive/negative) 9/3 8/10 0.20 PET at baseline (AD: typical/atypical) 11/1 2/16 <0.001 Duration of symptoms* (y) 3 ± 1.7 2.3 ± 2.2 0.35 Years of education* 12.4 ± 3.7 11.1 ± 3.2 0.31 Diagnostic approach PET APOE PET and APOE PET or APOE Sensitivity (%) 92 75 67 100 Specificity (%) 89 56 100 44 Test accuracy (%) 90 63 87 67 PPV (%) 85 53 100 55 NPV (%) 94 77 82 100 PET = MCI patients with Alzheimer-suggestive PET scan at baseline were classified as test positive; APOE = MCI patients with APOE ε4–positive genotype were classified as test positive; PET and APOE = MCI patients with Alzheimer-suggestive PET scan and APOE ε4–positive genotype at baseline were classified as test positive; PET or APOE = MCI patients with Alzheimer-suggestive PET scan or APOE ε4–positive genotype were classified as test positive.
In this issue
Jump to section
Related Articles
Cited By...
- 18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies
- Predicting the Progression of Mild Cognitive Impairment Using Machine Learning: A Systematic, Quantitative and Critical Review
- VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimers Disease
- Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
- Diagnostic Value of 18F-FDG PET/CT Versus MRI in the Setting of Antibody-Specific Autoimmune Encephalitis
- Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies
- Predictive value of APOE-{varepsilon}4 allele for progression from MCI to AD-type dementia: a meta-analysis
- Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study
- Tarot decks and PET scans: Predicting the future of MCI
- Comparing predictors of conversion and decline in mild cognitive impairment
- Comparison of 18F-FDG and PiB PET in Cognitive Impairment
- Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
- Fluorodeoxyglucose-Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis
- Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias
- Positron emission tomography imaging in dementia
- Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism
- Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT
- 18F-FDG PET Database of Longitudinally Confirmed Healthy Elderly Individuals Improves Detection of Mild Cognitive Impairment and Alzheimer's Disease